Ultra-Early Tirofiban After Thrombolysis in Noncardioembolic Acute Ischemic Stroke

10 Mar 20264 min read0 viewsJournal Feed

GIST

Journal of the American Heart Association, Volume 15, Issue 6 , March 17, 2026. BackgroundSecondary platelet activation peaks ≈2 hours after intravenous thrombolysis with alteplase.

This study evaluated the safety and efficacy of ultra‐early tirofiban administration and compared different tirofiban regimens following intravenous thrombolysis in patients with noncardioembolic acute ischemic stroke.MethodsThis observational study enrolled patients with acute ischemic stroke who received tirofiban within 24 hours following intravenous thrombolysis. Patients were divided into ultra‐early (within 2 hours) and early (2–24 hours) groups based on tirofiban initiation time.

A secondary analysis was performed based on whether the tirofiban regimen included a bolus dose. The primary outcome was 90‐day excellent functional outcome (modified Rankin Scale score 0–1).

The safety outcomes included symptomatic intracranial hemorrhage, intracranial hemorrhage, and 3‐month all‐cause mortality.ResultsA total of 472 patients were enrolled, with 214 in the ultra‐early tirofiban group and 258 in the early tirofiban group. The ultra‐early tirofiban group was associated with 3‐month excellent functional outcomes (67.5% versus 53.3%; adjusted odds ratio [aOR], 1.56 [95% CI, 1.01–2.42]).

Clinical Editorial

Scope and objective signals

The study examines safety and efficacy of ultra-early tirofiban after intravenous thrombolysis with alteplase in noncardioembolic acute ischemic stroke.
It also probes whether a bolus-containing regimen differs from a maintenance-only approach after thrombolysis.

Design and population context

This is an observational cohort analysis enrolling patients who received tirofiban within 24 hours of intravenous thrombolysis.
Participants were stratified by initiation timing: ultra-early tirofiban within 2 hours versus early initiation from 2 to 24 hours.
A secondary comparison categorized regimens by presence or absence of a bolus dose following thrombolysis.
The sample comprised 472 patients: 214 in the ultra-early group and 258 in the early group.

Intervention exposure details

Ultra-early regimens initiated within 2 hours of alteplase serve as the primary exposure of interest.
A secondary exposure compared bolus-containing versus maintenance-only tirofiban regimens post-thrombolysis.

Primary and secondary outcomes

Primary efficacy outcome: 90‑day excellent functional outcome defined as modified Rankin Scale score 0–1.
Safety outcomes included symptomatic intracranial hemorrhage, intracranial hemorrhage of any type, and all-cause mortality at 3 months.

Key findings and statistical interpretation

Excellent functional outcomes at 3 months were more frequent with ultra-early tirofiban (67.5%) compared with early initiation (53.3%), with an adjusted odds ratio of 1.56 (95% CI, 1.01–2.42).
There were no statistically significant differences in intracranial hemorrhage (3.7% vs 1.6%; P=0.18), symptomatic intracranial hemorrhage (0.5% vs 0.4%; P=0.99), or 3‑month mortality (1.5% vs 2.5%; P=0.94) between ultra-early and early groups.
Propensity score matching yielded consistent results, supporting the robustness of the directional signal for functional benefit without increasing major hemorrhagic risk.
In the bolus versus maintained-dose comparison, there were no significant differences in excellent functional outcomes (61.4% vs 71.0%; aOR 0.68, 95% CI 0.36–1.30) or symptomatic intracranial hemorrhage (0.4% vs 0%; P=0.99).

Context and limitations

The analysis is observational and designed to adjust for confounding via multivariable adjustment and propensity matching; residual confounding cannot be excluded.